

AMENDMENT AND RESPONSE TO OFFICE ACTION
U.S.S.N. 10/522,595RECEIVED
CENTRAL FAX CENTER

JUL 28 2008


Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1 -46. (Cancelled)

47. (New) A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof



(I)

wherein

X and X' taken together form $-C(R_5)=N-$;Y is $-C(R_5)-$ and taken together with the carbon atom bearing the phenyl group forms a double bond and R₁ is absent;Y' is $-N(R_5)-$;

Z forms a covalent single bond between X' and Y';

R₂ and R₄ are independently selected from hydrogen and C₁₋₃alkyl;R₃ is selected from C₁₋₃alkyl and (A)_mR₁₂; $-C(R_5)-$ is selected from $-C(H)-$ and $-C(C_{1-20}alkyl)-$; $-N(R_5)-$ is selected from $-N(H)-$ and $-N(C_{2-20}alkyl)-$;

m is 0;

07/29/2008 PCHOMP 00000001 10552595

02 FC:2201


105.00 0P

AMENDMENT AND RESPONSE TO OFFICE ACTION
U.S.S.N. 10/522,595

R₁₂ is selected from the group consisting of OH, SH, NH₂, halo, NO₂, C(R₁₇)₃, OC(R₁₇)₃ and CN;

R₁₇ is independently selected from hydrogen and halogen; and
 wherein each alkyl may be optionally substituted.

48. (New) A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof



(I)

wherein

X and X' taken together form -C(R₅)=N-;

Y is -C(R₅)- and taken together with the carbon atom bearing the phenyl group forms a double bond and R₁ is absent;

Y' is -N(R₅)-;

Z forms a covalent single bond between X' and Y';

R₂ and R₄ are independently selected from hydrogen and C₁₋₃alkyl;

R₃ is selected from C₁₋₃alkyl and (A)_mR₁₂;

-C(R₅)- is selected from -C(H)- and -C(C₁₋₂₀alkyl)-;

-N(R₅)- is selected from -N(alkyl)- wherein alkyl is selected from the group consisting of ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, t-butyl, cyclobutyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, cyclopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1-propylpropyl, 2-propylpropyl and cyclohexyl;

AMENDMENT AND RESPONSE TO OFFICE ACTION
U.S.S.N. 10/522,595

m is 0;

R₁₂ is selected from the group consisting of OH, SH, NH₂, halo, NO₂, C(R₁₇)₃, OC(R₁₇)₃ and CN;

R₁₇ is independently selected from hydrogen and halogen; and
wherein each alkyl may be optionally substituted.

49. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein

Y is -CH-; and

X is -CH-.

50. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R₃ is OC(R₁₇)₃.

51. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R₃ is C₁₋₃alkyl.

52. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R₃ is -CH₃ or -OCH₃.

53. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein N(R₅)- is 3-methylbutyl.

54. (New) A compound wherein the compound is 4-(4-methoxyphenyl)-1-(3-methylbutyl)-1H-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

55. (New) A compound wherein the compound is 1-(3-methylbutyl)-4-(4-methylphenyl)-1H-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

56. (New) A pharmaceutical composition comprising a compound according to any one of claims 47, 48, 54 or 55, and a pharmaceutically acceptable carrier, diluent or excipient.

57. (New) The pharmaceutical composition according to claim 56 further comprising a glucocorticoid.